Vaxxinity (VAXX) Competitors $0.0010 0.00 (0.00%) (As of 11/4/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends VAXX vs. TCBP, DRMA, PTEIQ, IGNY, BLPH, NEXI, SEEL, SMFL, BDRX, and PRFXShould you be buying Vaxxinity stock or one of its competitors? The main competitors of Vaxxinity include TC Biopharm (TCBP), Dermata Therapeutics (DRMA), PolarityTE (PTEIQ), Ignyte Acquisition (IGNY), Bellerophon Therapeutics (BLPH), NexImmune (NEXI), Seelos Therapeutics (SEEL), Smart for Life (SMFL), Biodexa Pharmaceuticals (BDRX), and PainReform (PRFX). These companies are all part of the "pharmaceutical products" industry. Vaxxinity vs. TC Biopharm Dermata Therapeutics PolarityTE Ignyte Acquisition Bellerophon Therapeutics NexImmune Seelos Therapeutics Smart for Life Biodexa Pharmaceuticals PainReform TC Biopharm (NASDAQ:TCBP) and Vaxxinity (NASDAQ:VAXX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, profitability, community ranking, valuation, risk and institutional ownership. Which has more risk & volatility, TCBP or VAXX? TC Biopharm has a beta of 0.25, indicating that its share price is 75% less volatile than the S&P 500. Comparatively, Vaxxinity has a beta of 0.94, indicating that its share price is 6% less volatile than the S&P 500. Does the MarketBeat Community favor TCBP or VAXX? Vaxxinity received 4 more outperform votes than TC Biopharm when rated by MarketBeat users. However, 50.00% of users gave TC Biopharm an outperform vote while only 38.46% of users gave Vaxxinity an outperform vote. CompanyUnderperformOutperformTC BiopharmOutperform Votes150.00% Underperform Votes150.00% VaxxinityOutperform Votes538.46% Underperform Votes861.54% Is TCBP or VAXX more profitable? Company Net Margins Return on Equity Return on Assets TC BiopharmN/A N/A N/A Vaxxinity N/A N/A N/A Does the media favor TCBP or VAXX? In the previous week, TC Biopharm had 1 more articles in the media than Vaxxinity. MarketBeat recorded 1 mentions for TC Biopharm and 0 mentions for Vaxxinity. TC Biopharm's average media sentiment score of 0.00 equaled Vaxxinity'saverage media sentiment score. Company Overall Sentiment TC Biopharm Neutral Vaxxinity Neutral Do analysts recommend TCBP or VAXX? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TC Biopharm 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/AVaxxinity 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/A Which has preferable valuation and earnings, TCBP or VAXX? TC Biopharm has higher revenue and earnings than Vaxxinity. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTC Biopharm$4.76M0.15-$7.35MN/AN/AVaxxinity$70K1.81-$56.93M-$0.450.00 Do institutionals & insiders hold more shares of TCBP or VAXX? 16.3% of TC Biopharm shares are owned by institutional investors. Comparatively, 82.9% of Vaxxinity shares are owned by institutional investors. 15.4% of TC Biopharm shares are owned by company insiders. Comparatively, 64.1% of Vaxxinity shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. SummaryVaxxinity beats TC Biopharm on 5 of the 9 factors compared between the two stocks. Ad Porter & CompanyRigged election? Porter Stansberry’s viral Breaking Point 2024 broadcast has now been by tens of thousands of Americans who finally understand the grim reality of our next election. With November 5 just around the corner, it’s imperative for your financial future that you read Porter’s message below now and then watch Breaking Point before it’s too late. Watch this video, it is being taken down Monday night Get Vaxxinity News Delivered to You Automatically Sign up to receive the latest news and ratings for VAXX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VAXX vs. The Competition Export to ExcelMetricVaxxinityPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$127,000.00$6.75B$5.04B$8.43BDividend YieldN/A7.94%7.52%4.16%P/E Ratio0.0012.17130.2316.67Price / Sales1.81270.431,720.2276.26Price / CashN/A46.0936.9133.54Price / Book0.015.284.604.98Net Income-$56.93M$151.33M$114.94M$224.26M7 Day PerformanceN/A0.30%0.14%1.65%1 Month PerformanceN/A14.88%10.15%6.92%1 Year PerformanceN/A36.87%33.87%26.46% Vaxxinity Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VAXXVaxxinityN/A$0.00flatN/A-99.8%$127,000.00$70,000.000.0090Gap UpTCBPTC Biopharm0.6248 of 5 stars$1.62-4.7%N/A-99.9%$859,000.00$4.76M0.0041DRMADermata Therapeutics2.1579 of 5 stars$1.39-4.8%$6.00+331.7%-90.0%$781,000.00N/A-0.068Gap UpPTEIQPolarityTEN/A$0.11flatN/A+1,050.0%$769,000.00$810,000.00-0.0360IGNYIgnyte AcquisitionN/A$0.07flatN/AN/A$510,000.00N/A0.003BLPHBellerophon Therapeutics0.3633 of 5 stars$0.04flatN/A-7.7%$440,000.00$5.64M-0.0420NEXINexImmuneN/A$0.27flatN/A-92.5%$371,000.00N/A-0.0170SEELSeelos TherapeuticsN/A$0.99-22.0%N/A-99.9%$368,000.00$2.20M0.0020SMFLSmart for LifeN/A$0.05flatN/A-99.8%$354,000.00$8.23M0.00110BDRXBiodexa Pharmaceuticals1.9553 of 5 stars$6.66+2.3%$200.00+2,903.0%N/A$333,000.00$470,000.000.0021Gap DownPRFXPainReform1.7648 of 5 stars$0.56-6.7%$2.00+257.1%-80.9%$324,000.00N/A-0.024 Related Companies and Tools Related Companies TC Biopharm Competitors Dermata Therapeutics Competitors PolarityTE Competitors Ignyte Acquisition Competitors Bellerophon Therapeutics Competitors NexImmune Competitors Seelos Therapeutics Competitors Smart for Life Competitors Biodexa Pharmaceuticals Competitors PainReform Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:VAXX) was last updated on 11/4/2024 by MarketBeat.com Staff From Our Partners2 sentences that change everything you THOUGHT you knew about tradingIf you're like most people, on Friday morning you'll probably follow your set routine: Wake up... eat breakfas...Investing Daily | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredElection warning coming true… If you missed it, my emergency election broadcast is now available - watch it before it's too late.Porter & Company | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredA Totally New ‘Income Coin’Buckle up… Because this might shatter everything you thought you knew about "income trading." In fact, i...Crypto 101 Media | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | SponsoredA new way to play the AI boom (act before November 19)There's a new way to play the $15 trillion AI boom. And it's so simple - you can do it right now with as li...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaxxinity, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vaxxinity With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
